Ainos Gestion

Gestion contrôle des critères 0/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Chun-Hsien Tsai

Directeur général

US$3.8m

Rémunération totale

Pourcentage du salaire du PDG	2.6%
Durée du mandat du directeur général	2.9yrs
Propriété du PDG	5.9%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	2.9yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Chun-Hsien Tsai a-t-elle évolué par rapport aux bénéfices de Ainos?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Dec 31 2023	n/a	n/a	-US$14m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$15m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$4m	US$100k	-US$14m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$7m
Mar 31 2022	n/a	n/a	-US$5m
Dec 31 2021	US$82k	US$45k	-US$4m

Rémunération vs marché: La rémunération totale de Chun-Hsien ($USD 3.82M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 478.33K ).

Rémunération et revenus: La rémunération de Chun-Hsien a augmenté alors que l'entreprise n'est pas rentable.

PDG

Chun-Hsien Tsai (53 yo)

2.9yrs

Titularisation

US$3,816,959

Compensation

Mr. Chun-Hsien Tsai has been Chairman of Board, President and Chief Executive Officer at Ainos, Inc. since April 15, 2021 and served as its Chief Financial Officer since April 15, 2021 until August 11, 202...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Chun-Hsien Tsai	Chairman of Board	2.9yrs	US$3.82m	5.9% € 527.8k
Yao-Chung Chiang	Independent Director	2.9yrs	US$266.11k	1.17% € 105.0k
Pao-Sheng Wei	Independent Director	1.8yrs	US$249.75k	1.13% € 101.1k
Wen-Han Chang	Independent Director	2.9yrs	US$271.00k	2.27% € 203.1k
Ting-Chuan Lee	Director	2.9yrs	pas de données	1.73% € 154.5k
Chun-Jung Tsai	Director	2.9yrs	pas de données	1.2% € 107.0k
Chung-Yi Tsai	Director	2.9yrs	US$261.76k	1.13% € 101.1k

2.9yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la FZX n'est pas considéré comme expérimenté ( 2.9 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Ainos Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Ainos, Inc., Annual General Meeting, Sep 27, 2024

Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Less than half of directors are independent

Ainos, Inc. Announces Chief Financial Officer Changes

Recent updates

Ainos, Inc. Announces Institutional Review Board Approval for Sjögren’S Syndrome Clinical Study

Ainos, Inc. Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies

Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for HIV-Oral Warts Clinical Trial

Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for Hiv-Oral Warts Clinical Trial, Highlighting Value of Fda-Designated Orphan Drug Veldona

Ainos Announces Plan to Initiate Taiwan Clinical Study for Veldona as Potential Treatment of Oral Warts in HIV-Positive Patients

Ainos, Inc. Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety

Ainos, Inc., Annual General Meeting, Sep 27, 2024

Ainos, Inc Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug

Ainos Receives a Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market

Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms

Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement

Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell

Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary

Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Ainos, Inc., Annual General Meeting, Dec 08, 2023

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.20 loss in 2Q 2022)

Less than half of directors are independent

Staff of Nasdaq Determines Ainos is Eligible for an Additional 180 Calendar Day Period, or Until January 2, 2024, to Regain Compliance with Its Minimum Bid Price Requirement

Ainos, Inc. Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20 Million Revenue Target

Ainos, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.22 loss in 1Q 2022)

Less than half of directors are independent

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen